NEWS
Studies Support Expanded Role for Lenalidomide in Treating Multiple Myeloma
Maintenance therapy with the drug lenalidomide (Revlimid) substantially lengthens the time patients with multiple myeloma live without their cancers progressing, according to the results of three randomized placebo-controlled clinical trials published May 10 in the New England Journal of Medicine. Overall survival was also improved in one of the trials, but according to several researchers, that conclusion is less definitive.
The results also showed that lenalidomide maintenance therapy carries an increased risk of second primary cancers. Read more > >
Low-Dose Radioactive Iodine Destroys Thyroid Tissue Left after Surgery
Whether low-risk patients should receive radioactive iodine at all remains a questionSequencing Study Identifies Gene that May Contribute to Melanoma
PREX2 gene, chromosomal rearrangements may play important roles in the diseaseExperimental Gene Therapy Protects Normal Cells from Toxic Effects of Chemotherapy
Protecting normal blood cells allows aggressive treatment for brain tumor patientsAlso in the News: Sunburn and Indoor Tanning Still Common
Unearthing Clues to Cancer Risk in the Aging Genome
Some healthy individuals have unexpected chromosome anomalies, which appear to increase with ageComplex Immune-Based Cancer Treatment Shows Signs of Progress
Genetically engineered T cells are being studied for a variety of cancers, but hurdles to clinical use remain"Rewiring" Cells to Treat an Aggressive Breast Cancer
Study of signaling networks in cancer cells reveals potential treatmentFeatured Clinical Trial: Experimental Antibody for Treatment-Resistant Liver Cancer
Will new biological agent prolong time to disease progression in patients who didn't benefit from sorafenib?
.png)
No hay comentarios:
Publicar un comentario